Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin

Journal of Bioenergetics and Biomembranes

Volumn 45, Issue 5, 2013, Pages 467-475

  Tavares Valente, Diana ^a   Baltazar, Fátima ^b,c   Moreira, Roxana ^a,c   Queirós, Odília ^a,c  

^a INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

Author keywords

"Warburg effect"; Bioenergetic modulators; Extracellular pH; Multidrug resistance (MDR)

Indexed keywords

ADENOSINE TRIPHOSPHATE; DOXORUBICIN; PACLITAXEL;

ARTICLE; BIOENERGY; BREAST CANCER; CANCER CELL; CELL METABOLISM; CELL MIGRATION; CYTOSOL; DEPLETION; HUMAN; HUMAN CELL; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASM; PH MEASUREMENT; PHENOTYPE; TUMOR MICROENVIRONMENT;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; PACLITAXEL;

EID: 84885635871     PISSN: 0145479X     EISSN: 15736881     Source Type: Journal    
DOI: 10.1007/s10863-013-9519-7     Document Type: Article

References (41)

1. Belotti D, Rieppi M, Nicoletti MI (1996) Paclitaxel (TAXOL(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin Cancer Res 2:1725-1730
2. Brum G et al (2013) N-acetylcysteine potentiates doxorubicin-induced ATM and p53 activation in ovarian cancer cells. Int J Oncol 42:211-219
3. Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457-473
4. Chaudhari AA et al (2008) Mitochondrial transmembrane potential and reactive oxygen species generation regulate the enhanced effect of CCCP on TRAIL-induced SNU-638 cell apoptosis. J Vet Med Sci 70:537-542
5. Choi HJ et al (2008) Hexane/Ethanol of Glycyrrhiza Uralensis Licorice suppresses doxorubicin-induced apoptosis in H9c2 rat cardiac myoblasts. Exp Biol Med 233:1554-1560
6. Coley HM (2008) Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34:378-390
7. Daniel C et al (2013) The role of proton dynamics in the development and maintenance o multidrug resistance in cancer. Biochim Biophys Acta. doi: 10.1016/j.bbadis.2013.01.020
8. Ferguson R, Jackson S, Stanley A, Joyce A, Harnden P, Morrison E, Patel P, Phillips R, Selby P, Banks R (2005) Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer 115:155-163
9. Gatenby RA et al (2007) Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 97:646-653
10. Gillies RJ, Gatenby RA (2007) Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 26:311-317
11. Gillies RJ et al (2004) pH Imaging: a review of Ph measurement methods and applications in cancers. Eng Med Biol Mag 2:57-64
12. Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49:24-42
13. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627
14. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
15. Granchi C, Minutolo F (2012) Anticancer agents that counteract tumor glycolysis. Chem Med Chem 7:1318-1350
16. Gregory RE, DeLisa AF (1993) Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm 12:401-415
17. Hall M, Handley M, Gottesman M (2009) Is resistance useless? Multidrug resistance and collateral sensivity. Trends Pharmacol Sci 30:546-556
18. Heiden V, Matthew G (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10:671-684
19. Hennequin C, Giocanti N, Favaudon V (1996) Interaction of ionizing radiation with paclitaxel (taxol) and docetaxel (taxotere) in Hela and SQ20B cells. Cancer Res 56:1842-1850
20. Izumi H et al (2003) Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 29:541-549
21. Larsen A, Escargueil EA, Skladanowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217-229
22. Maher JC, Krishan A, Lampidis TJ (2004) Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 53:116-22
23. Moreno-Sánchez R et al (2007) Energy metabolism in tumor cells. FEBS J 274:1393-1418
24. Moutasim KA, Nystrom ML, Thomas GJ (2011) Cell migration and invasion assays. Methods Mol Biol 731:333-43
25. Neri D, Supuran CT (2011) Interfering with pH regulation in tumours as a therapeutic strategy. Discovery Nat Rev Drug Discov 10:767-777
26. Papandreou I, Goliasova T, Denko NC (2011) Anticancer drugs that target metabolism: is dichloroacetate the new paradigm? Int J Cancer 128:1001-1008
27. Queirós O et al (2012) Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. J Bioenerg Biomembr 44:141-153
28. Raghunand N, Gillies RJ (2000) pH and drug resistance in tumors. Drug Resist Updat 3:39-47
29. Robey IF, Martin NK (2011) Bicarbonate and dicholoroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer 11:1-10
30. Rohwer N, Cramer T (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14:191-201
31. Stockwin LH et al (2010) Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int J Cancer 127:2510-2519
32. Swietach P, Vaughan-Jones RD, Harris AL (2007) Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26:299-310
33. Thews O et al (2006) Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 8:143-152
34. Tong J et al (2011) Synergistic antitumor effect of dichloroacetate in combination with 5-Fluorouracil in colorectal cancer. J Biomed Biotechnol 2011:1-7
35. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
36. Wartenberg M et al (2010) Glycolytic pyruvate regulates P-Glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state. J Cell Biochem 109:434-446
37. Webb BA et al (2011) Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 11:671-677
38. Weljie AM, Jirik FR (2011) Hypoxia-induced metabolic shifts in cancer: moving beyond the Warburg effect. Int J Biochem Cell Biol 43:981-989
39. Williams AC, Collard TJ, Paraskeva C (1999) An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene 18:3199-3204
40. Yuan J, Narayanan L, Rockwell S (2000) Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 60:4372-4376
41. Zong ZP et al (2004) Phorbol myristate induces apoptosis of taxol-resistant sarcoma cells in vitro. Eur J Pharmacol 489(1-2):3-11